$3M Private Placement with Warrants Announced by Co-Diagnostics
CODX sits 73% above its 52-week low of $1.26 on elevated volume (36× avg).
Summary
Co-Diagnostics announced a $3.0 million private placement of common stock (or pre-funded warrants) and accompanying warrants to institutional investors. The offering price is $1.821 per share/warrant combination, with warrants exercisable at $1.571. This financing is critical given the company's recent Q1 2026 earnings report, which revealed a wider loss, significant cash burn, and a reiterated 'going concern' warning, alongside the expiration of its primary ATM program. The $3.0 million raise is highly material, representing a substantial portion of the company's current market capitalization, indicating significant dilution for existing shareholders. While necessary to address liquidity issues, the terms, including the issuance of warrants, suggest further potential dilution. Investors should monitor the closing of this offering and any subsequent capital raises, as the company's financial health remains precarious.
At the time of this announcement, CODX was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $1.26 to $46.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: PR Newswire.